IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4181
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$2M
James M. Rolke
Revelation Biosciences, Inc. focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti-viral nasal drop for the prevention or treatment of respiratory viral infections.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$REVB REVELATION BIOSCIENCES, INC. | 34 | 23 | 22 | 22 | - | - | -78.6% | -67.2% | - | - | - | - | 0.0% | 17.0x | $2M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
REVELATION BIOSCIENCES, INC. (REVB) receives a "Avoid" rating with a composite score of 34.3/100. It ranks #4181 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
James M. Rolke
Chief Executive Officer
Labor Force
10
23
27
30
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for REVB
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for REVB.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -78.6% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags REVELATION BIOSCIENCES, INC. with an Avoid rating, assigning a composite score of 34.3/100 and 1 out of 5 stars. Ranked #4181 of 7,333 stocks, REVB falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
REVELATION BIOSCIENCES, INC. registers a weak quality score of just 23/100, indicating significant profitability challenges. The company reports a return on equity of -78.6% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
REVB registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.34x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
REVELATION BIOSCIENCES, INC.'s investment score of 27/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -67.2% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
REVELATION BIOSCIENCES, INC. is experiencing notably weak momentum with a score of just 22/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of -0.41 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
REVB's stability score of 30/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -0.41 and a debt-to-equity ratio of 17.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 49/100 for REVB suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 17.00x), micro-cap liquidity risk. With a $2M market cap (micro-cap), REVELATION BIOSCIENCES, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
REVELATION BIOSCIENCES, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4181 of 7,333 overall (43rd percentile). Key comparisons include ROE of -78.6% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While REVB currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (22) would have the largest impact on the composite score.
ROE 3068% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 8400% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate REVELATION BIOSCIENCES, INC. (REVB) as Avoid with a composite score of 34.3/100 at a current price of $1.35. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (30th percentile) and investment (27th percentile), which together account for the majority of the composite score. Offsetting weakness in value (22th percentile) and momentum (22th percentile) tempers our overall conviction. We assign a No Moat rating (21/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
REVELATION BIOSCIENCES, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.3/100 places it at rank #4181 in our full 7,333-stock universe. At $2M in market capitalization, REVELATION BIOSCIENCES, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (22th percentile) suggest caution regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for REVELATION BIOSCIENCES, INC., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $1.35, REVELATION BIOSCIENCES, INC. is trading at a premium to fundamental value. Our value factor score of 22/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.3x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (17% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 34.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Weak momentum (22th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (23th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Medium uncertainty rating to REVELATION BIOSCIENCES, INC.. The stock presents a balanced risk profile: below-average price stability (30th percentile) and weak quality scores (23th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: below-average price stability (30th percentile); weak quality scores (23th percentile); low beta of -0.41 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 30th percentile and quality factor at the 23th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (17% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate REVELATION BIOSCIENCES, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-78.6%), weak asset returns (ROA -67.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — REVELATION BIOSCIENCES, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, REVELATION BIOSCIENCES, INC. receives a Avoid rating with a composite score of 34.3/100 (rank #4181 of 7,333). Our quantitative framework assigns a No Moat (21/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 25/100.
Our analysis does not support a constructive view on REVELATION BIOSCIENCES, INC. at this time. The combination of limited competitive advantages, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign REVELATION BIOSCIENCES, INC. a meaningful economic moat, scoring 21/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (8.9/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage N/A. These pillars form the core of REVELATION BIOSCIENCES, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect REVELATION BIOSCIENCES, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 23/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -78.6% and ROA of -67.2%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -78.6% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 17%. The sector median D/E is 0%, putting REVELATION BIOSCIENCES, INC. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
U.S. stock futures declined slightly on Friday after two consecutive days of gains, following President Trump's withdrawal of EU tariffs and better-than-expected Q3 GDP figures at 4.4%. Key movers include Intel down 12% on weak guidance, Capital One down 3.31% on earnings miss, Revelation Biosciences up 38% on FDA approval pathway, and CSX up 2.99% despite missing estimates. Bank of America's fund manager survey shows institutional investors at their most bullish since 2021.
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. ...
- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life ...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. BIOLASE, Inc. (NASDAQ: BIOL) On Jan. 29, Biolase reported full-year 2023 interim revenue of $48.9 million to $49.2 million, up 1% year-over-year compared to the consensus of $49.21 million. The company’s stock fell around 43% over the past five days ...
Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results. Skechers said fourth-quarter revenue increased 4.4% year-over-year to $1.96 billion, which missed the consensus estimate of $2.03 billion, according to Benzinga Pro. The company reported quarterly earnings of 56 cents per share, which beat analyst estimates of 54 cents per share. Skechers shares fell 6.9% to $59.21 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares jumped 77.6% to $4.28. Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million. Minim, Inc. (NASDAQ: MINM) shares rose 34.4% to $6.76 after gaining more than 22% on Thursday. Remark Holdings, Inc. (NASDAQ: MARK) shares climbed 33% to $0.6802. Kopin Corporation (NASDAQ: KOPN) jumped 30% to $2.4050. BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 26.3% to $2.73. Mountain Crest Acquisition Corp. IV (NASDAQ: MCAF) gained 23% to $14.65. Tyra Biosciences, Inc. (NASDAQ: TYRA) gained 21.8% to $15.84. Tyra Biosciences announced a $200 million private placement financing. Meta Platforms, Inc. (NASDAQ: META) rose 18.9% to $469.34 as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share. CCSC Technology International Holdings Limited (NASDAQ: CCTG) gained 18.2% to $4.6099 after dipping around 82% on Thursday. Roma Green Finance Limited (NASDAQ: ROMA) gained 15.8% to $0.8697 after gaining around 5% on Thursday. Deckers Outdoor Corporation (NYSE: DECK) surged 14% to $879.03 after reporting better-than-expected third-quarter financial results. Trugolf, Inc. (NASDAQ: TRUG) shares jumped 14% to ...